N+1 Singer reiterated Verona Pharma PLC (LON:VRP) to Corporate in a statement released earlier today.
- Updated: September 25, 2016
Boasting a price of 3.40GBX, Verona Pharma PLC (LON:VRP) traded 4.70% higher on the day. With the last stock price up 4.53% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. Verona Pharma PLC has recorded a 50-day average of 3.18GBX and a two hundred day average of 3.28GBX. Trade Volume was up over the average, with 3,906,187 shares of VRP changing hands over the typical 1,483,790
N+1 Singer has reiterated Verona Pharma PLC (LON:VRP) to Corporate in a statement released on 9/26/2016.
See Chart Below
Verona Pharma PLC has a with a one year low of 2.17GBX and a one year high of 5.25GBX VRP’s total market value is presently 0 GBX.
General Company Details For Verona Pharma PLC (LON:VRP)
Verona Pharma plc is a specialist pharma company. The principal activity of the Company is the development of drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. Its lead drug, RPL554, a Phosphodiesterase 3 (PDE3)/PDE4 inhibitor with both bronchodilator and anti-inflammatory activities, is in Phase II trials as a nebulized treatment for acute exacerbations of COPD in a hospital setting. The Company is also exploring the potential of the drug in cystic fibrosis, where it is in pre-clinical testing. Its VRP700 is in the clinical-stage. VRP700 is a potential anti-tussive (cough) drug. It carried out a pilot study, in which an inhaled dose of VRP700 inhibited coughing in a group of patients with chronic intractable cough due to underlying lung disease. The Company also carried out a clinical study to evaluate the efficacy of an inhaled dose of VRP700 in patients with chronic intractable cough.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.